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Introduction
Based on antigenic properties, human interferons (IFNs) can be divided into three main groups: IFNa, IFNf, and IFNy.
Because of the antiviral, antitumor, and immunoregulatory effects, IFNs have been used in a variety of diseases with varying clinical responses. A significant therapeutic problem has been the development of neutralizing antibodies in IFN-treated patients, which has been associated with response failure (1) (2) (3) (4) .
The immunogenicity of rIFNa2A seems to be higher than that of other IFNa preparations (5) .
Antibodies to IFNs have been reported in a few patients suffering from viral diseases, such as varicella zoster and viral hepatitis, and autoimmune diseases, such as systemic lupus erythematosus, chronic arthritis, and type I diabetes (6) (7) (8) (9) (10) (11) . Low levels of antibodies neutralizing IFNa, IFN/3, and IFN'y in vitro have also been reported in healthy blood donors (10, 12, 13) . It is not clear, however, whether these antibodies can be regarded as specific autoantibodies (aAb) to IFNs (13) . Immunoglobulin therapy has been reported to be beneficial in many infectious and immunoinflammatory diseases, and various IEN species may be pathogenetically involved in some of these diseases (14, 15) . Recently, a pharmaceutical preparation of normal human IgG was found to suppress the antiviral effect of IFNa ( 12) .
In this paper, we have characterized IFN-binding and -neutralizing autoantibodies in normal and hyperimmune human IgG preparations.
Methods
Human IgG preparations. Five batches of normal human IgG from each of three manufacturers were used. (a) 30 mg/ml Sandoglobulin® (S1-S5) (Sandoz, Copenhagen, Denmark); (b) 50 mg/ml Gammagard® (G1-G5) ( 10 ,000 cells/well and incubated at 370C in a 5% CO2 air atmosphere. The IFNa and IFN/3 preparations were added at a concentration of 3 IU/ml; IFNy was used at a concentration of 10 IU/ml. After 24 h of incubation, EMC virus was added at a concentration which caused 100% cell death after 26 h. After another 24 h, the antiviral effect of IFN was measured using the 3-(4,5 dimethyl thiazol-2-yl)-2,5-difenyl tetrazolium bromid (MTT) assay as described (16 IgG preparations and the international standard IFNa2A mAb were diluted in 0.02 M phosphate-buffered saline, pH 7.4 (PBS), containing 0.1% gelatin, 0.1% Triton X-100 (PBS-GTX), or in RPMI 1640 for use in ANB, and coincubated with 1"I-labeled and unlabeled rIFNa2A.
Coincubation was carried out at room temperature followed by overnight incubation at 4°C in 100 A1 containing 3,000 cpm of '`'I-rIFNa2A with or without > 200 times excess of unlabeled rIFNa2A.
Binding of IgG to rIFNa2A was analyzed by molecular size chromatography at 4°C by the use of columns containing 10 ml of Sephadex superfine G75 (Pharmacia, Uppsala, Sweden) with a running buffer of PBS-GTX or RPMI 1640 (12) .
Binding of IgG to rIFNa2A was also investigated by use of IgGFc affinity chromatography on columns with 500 is protein G Sepharose CL-4B (Pharmacia). Bound and free tracer were separated at 4°C with PBS-GTX as running buffer. Elution of bound material was carried out using 100 mM glycine-HCl, pH 2.4. Nonspecific binding was assessed in the presence of 200 ng unlabeled rIFNa2A.
The binding potential was defined as the reciprocal value of the dilution of 15 mg IgG/ml causing significant binding of 3,000 cpm/ 100 .I of '25I-rIFNa2A (> 3 times SD). Radioactivity was determined with an error < 5% in a gamma counter (1272 CliniGamma, LKB, Wallac, OY, Finland).
Avidities were measured as previously described ( 18). 125I-rIFNa2A
was used at concentrations from 40 to 400 pg/ml. Unlabeled rIFNa2A
was added up to a maximum of 50 ng/ml. '"I-rIFNa2A and unlabeled rIFNa2A were titrated against the international standard. Fixed IgG levels were titrated against varying tracer and competitor concentrations using protein G chromatography. (19, 20 To study the specificity of the IFN neutralization, rIFNa2A, rIFNa2C, ly-IFNaNI, and IFN/3, at concentrations inducing 90% protection against challenge virus, were incubated with serial dilutions of IgG preparation. Fig. 1, upper panel, shows the results using FSME at concentrations from 7.5 mg/ml and twofold dilution to 50 Iug/ml. A 50% reduction in antiviral activity was observed at IgG concentrations of 0.5 mg/ml (rIFNa2A), 1.5 mg/ml (rIFNa2C), 2.5 mg/ml (ly-IFNaNl), and 7.9 mg/ml (rIFN/3). FSME did not neutralize the antiviral effect of rIFNy (not shown). A pool of normal human IgG showed a similar inhibitory pattern, but higher IgG levels were needed for neutralization (Fig. 1, lower panel) IgG preparation (mg/ml) Figure 1 . Reduction of IFN-induced antiviral activity afforded by Fruhsommer meningoencephalitis IgG (FSME) or Sandoglobuling (S3+S4). FSME and the S3+S4 pool were tested against rIFNa2A (-), rIFNa2C
(A), ly-IFNaN1 (m), and rIFNP (o); each IFN preparation was tested at the lowest concentration inducing 90% protection against EMC virus.
the ability of normal IgG to bind and to neutralize IFNa (Fig.  3) . More than 80% of the binding was achieved after 10 min at 370C, whereas < 30% bound after 10 min at 40C. In the presence of 500-fold excess rIFNa2A, dissociation of the antigen/antibody complex was slow (T/2 > 48 h at 370C, n = 5).
IgG subclass distribution of IFNa binding antibodies. Affinity chromatography using protein-G columns demonstrated recovery of > 90% as compared with Sephadex G75. IgG subclass-specific affinity chromatography, carried out on a pool of anti-IFNa positive IgG preparations, showed that the majority of antibodies was of the IgG1 subclass. Only traces of IgG2, IgG3, and IgG4 were found (Fig. 4) Fig. 4 ). Specificity ofthe IFNa binding antibodies. Using IgG preparation S4 and '25I-rIFNa2A at a B/F ratio of 0.64, competition with unlabeled IFN preparations revealed a clear pattern of specificity. Unlabeled rIFNa2A, 0.1 ng/ml, reduced the B/F value by > 50%, while 1 ng/ml was needed for the same reduction by rIFNa2C or ly-IFNaNI (Fig. 5) Bound (% cpm) Figure 2 . Binding of '25I-rLFNa2A to human IgG measured by molecular size chromatography on Sephadex G75 columns. '25I-rLFNa2A, 3 ,000 cpm in 100 ILI (=100%), and 10 mg/ml IgG were applied on each column. S1-S5: SandoglobulinS preparations 1-5; G1-G5: Gammagard® preparations 1-5; N1-N5: Nordimmun® preparations 1-5.
10 mg/ml, reduced the binding of '25I-rIFNa2A to A549 cells by 78%, whereas the same concentration of S4 IgG inhibited by 60%. In contrast, the Ni IgG preparation, which was rIFNa2A antibody negative, failed to interact with the binding. Avidities and binding capacities of the antibodies to IFNa As shown in Table I , the avidities of FSME and three normal antibody-positive IgG preparations varied only slightly: Kd t 30 pM. In contrast, the maximum binding capacities varied considerably: from 27 to 490 pg/mg IgG (Table I ). The avidities were not influenced by varying the test concentrations of IgG to bind from 100 to 1,000 pg/ml of 1"I-rIFNa2A.
Binding of IFNa to human serum. Molecular size and protein-G chromatography demonstrated low binding of '25I-rIFNa2A in a pool of 40 normal serum samples (see Fig. 4 ). When individual sera were investigated, 8 of 40 serum samples showed minimal specific binding, which did not exceed 20% of 3,000 cpm of '"I-rIFNa2A added to each serum (50% serum in 100 tl).
Discussion
More than 10 years ago, antibodies which neutralized IFNa, but not IFNJ3 or IFNy, were reported in a patient with systemic lupus erythematosus (7) . Other case reports showed IFN antibodies before treatment in a patient with herpes-zoster and in two cancer patients (6, 21) . High neutralizing capacity IFN antibodies were detected in a patient with pure red cell aplasia, and non-neutralizing antibodies to rIFNa2A of IgM and IgG type were reported in patients with acute viral hepatitis (11, 22) . Naturally occurring antibodies to IFNa and IFN/I have been reported in Lou/c rats and in inbred mouse strains (23, 24 IFN (25) .
The discrepancy between the relatively high levels of IFN antibodies in human IgG preparations and the finding of seemingly low levels of specific anti-lENa IgG in only a few (20%) of the individual human sera may be explained by the presence in serum of IFNa/anti-IFNa IgG complexes which impede detection of the specific antibodies by added radiolabeled IFNa. It is also possible that the avidity of the anti-IFNa IgG molecules in human IgG prepared from more than 1,000 donors may be higher than that of anti-lENa IgG in individual donors due to a higher degree of polyclonality. Finally, since there was no sign of IgG-IgG interactions blocking the binding of rIFNa2A to the antibody preparations, it cannot be excluded that nonIgG blocking factors, for example IgM, exist in vivo and that these molecules are removed during the purification of pharmaceutically prepared IgG.
Naturally occurring antibodies to IL-la and 1L-6 have been demonstrated in healthy donors and in pharmaceutic IgG preparations; these antibodies, along with those against IFNa, may be of clinical importance and help to explain the efficacy of high-dose immunoglobulin therapy of certain immunoinflammatory and infectious diseases (14, 18, 26) .
In conclusion, high-avidity antibodies to IFNa and, to a lesser extent IFNI, are present in the majority of human IgG preparations. The specificities of these autoantibodies reflect the immunogenicity of the different LFNa preparations when used for therapeutic purposes. The presence of these antibodies may be beneficial in high-dose immunoglobulin therapy of conditions with excessive FENa production. On the other hand, it is theoretically possible that viral diseases may be negatively influenced by these antibodies.
